Philip Debbas
Overview
Explore the profile of Philip Debbas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey T, Pashkova A, et al.
Angew Chem Int Ed Engl
. 2024 Oct;
63(52):e202409446.
PMID: 39432331
Clinical biomarker development has been stymied by inaccurate protein quantification from mass spectrometry (MS) discovery data and a prolonged validation process. To mitigate these issues, we created the Targeted Extraction...
2.
Jacobs J, Spencer E, Helmus D, Yang J, Lagishetty V, Bongers G, et al.
Gut
. 2024 Aug;
73(12):1953-1964.
PMID: 39122361
Objective: IBD is characterised by dysbiosis, but it remains unclear to what extent dysbiosis develops in unaffected at-risk individuals. To address this, we investigated age-related patterns of faecal and serum...
3.
Fu Q, Vegesna M, Sundararaman N, Damoc E, Arrey T, Pashkova A, et al.
bioRxiv
. 2024 Apr;
PMID: 38562888
Clinical biomarker development has been stymied by inaccurate protein quantification from mass spectrometry (MS) discovery data and a prolonged validation process. To mitigate these issues, we created the Targeted Extraction...
4.
Lee Y, Li D, Mujukian A, Debbas P, Hampton M, Mengesha E, et al.
Inflamm Bowel Dis
. 2023 Sep;
30(8):1430-1434.
PMID: 37773982
No abstract available.
5.
Mujukian A, Kumar R, Li D, Debbas P, Botwin G, Cheng S, et al.
Inflamm Bowel Dis
. 2023 Aug;
30(4):602-616.
PMID: 37556401
Background: Vaccine hesitancy is prevalent among people with IBD, in part due to insufficient evidence regarding comparative safety of vaccines in this population. Methods: We conducted a nationwide comparative study...
6.
Li D, Debbas P, Mujukian A, Cheng S, Braun J, McGovern D, et al.
Inflamm Bowel Dis
. 2022 Aug;
29(6):883-887.
PMID: 35998072
Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown. Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose...
7.
Xu A, Li D, Ebinger J, Mengesha E, Elyanow R, Gittelman R, et al.
Front Immunol
. 2022 Apr;
13:880190.
PMID: 35464463
T-cells specifically bind antigens to induce adaptive immune responses using highly specific molecular recognition, and a diverse T-cell repertoire with expansion of antigen-specific clones can indicate robust immune responses after...
8.
Li D, Xu A, Mengesha E, Elyanow R, Gittelman R, Chapman H, et al.
Inflamm Bowel Dis
. 2022 Apr;
28(7):1130-1133.
PMID: 35397000
No abstract available.
9.
Li D, Debbas P, Cheng S, Braun J, McGovern D, Melmed G
medRxiv
. 2021 Dec;
PMID: 34909797
Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally of similar frequency, severity, and duration to those reported in the general population. The symptom profile...
10.
Li D, Xu A, Mengesha E, Elyanow R, Gittelman R, Chapman H, et al.
medRxiv
. 2021 Dec;
PMID: 34909785
Background: Vaccination against SARS-CoV-2 is a highly effective strategy to protect against infection, which is predominantly mediated by vaccine-induced antibodies. Postvaccination antibodies are robustly produced by those with inflammatory bowel...